Nurix Therapeutics (NRIX) Receivables - Net (2020 - 2025)

Nurix Therapeutics (NRIX) has 6 years of Receivables - Net data on file, last reported at $5.0 million in Q4 2025.

• On a quarterly basis, Receivables - Net changed 0.0% year-over-year to $5.0 million in Q4 2025; TTM through Nov 2025 was $5.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $5.0 million, changed 0.0% from the prior year.
• Receivables - Net for Q4 2025 stood at $5.0 million, down from $19.0 million in the prior quarter.
• Over the last five years, Receivables - Net for NRIX reached as high as $19.0 million in Q2 2025 and fell as low as $1.0 million in Q4 2022.
• Historically, Receivables - Net has averaged $4.9 million across 5 years, with a median of $5.0 million in 2021.
• Across the five-year window, Receivables - Net plunged 83.33% in 2022 and jumped 300.0% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $6.0 million in 2021, then plunged by 83.33% to $1.0 million in 2022, then soared by 300.0% to $4.0 million in 2023, then increased by 25.0% to $5.0 million in 2024, then changed by 0.0% to $5.0 million in 2025.
• Per Business Quant data, the three most recent Receivables - Net figures were $5.0 million in Q4 2025, $19.0 million in Q2 2025, and $7.0 million in Q1 2025.